Treatment Outcomes of Concurrent Chemoradiotherapy for Locally Advanced NSCLC: A Single-Center Experience

Abstract

Background: Locally advanced non-small cell lung cancer (NSCLC) poses a significant therapeutic challenge, often managed with concurrent chemoradiotherapy (CRT). Evaluating treatment outcomes in real-world settings is crucial for optimizing patient care. Objective: This study aimed to assess the treatment outcomes of concurrent CRT in patients with locally advanced NSCLC treated. Method: A prospective analysis was conducted on 90 patients at the Department of Radiation Oncology, Rajshahi Medical College Hospital, Rajshahi, from July 2020 to June 2022, with locally advanced NSCLC who received concurrent CRT during the period. Data on patient demographics, tumor characteristics, treatment regimens, response rates, and toxicities were collected from medical records. Treatment response was evaluated using RECIST criteria, and toxicities were graded based on CTCAE v5.0. Results: Among the 90 patients included, the median age was 60 years (range: 45-75 years), with 65% being male. Stage IIIA disease was predominant (70%). The overall response rate to concurrent CRT was 65%, comprising a complete response in 35% and a partial response in 30% of patients. In 20% of patients, stable disease was observed, while 15% experienced disease progression. Treatment- related toxicities were observed, with 40% experiencing grade 3/4 esophagitis, 25% pneumonitis, and 30% hematologic toxicities. The median progression-free survival was 12 months (95% CI: 10-14 months), and the median overall survival was 18 months (95% CI: 15-21 months). Conclusions: Concurrent CRT for locally advanced NSCLC at Rajshahi Medical College Hospital demonstrated favorable treatment responses with manageable toxicities. These findings underscore the effectiveness of concurrent CRT in real-world clinical practice. Further research is warranted to refine treatment strategies and enhance patient outcomes.